ArticleBMC infectious diseases2018
Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016.
Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters.Journal of clinical pharmacology · 2026Trial
- Epidemiological characteristics, genotype patterns, and treatment outcomes in chronic hepatitis C patients receiving direct-acting antivirals: a cohort study from Istanbul, Türkiye.BMC infectious diseases · 2026Observational
- Prevalence of Polypharmacy Among Patients with Chronic Liver Disease-A Narrative Literature Review.Journal of clinical medicine · 2025Review
- Direct-Acting Antivirals in Hepatitis C Treatment for Renal Impairment: Liver Safety Concerns and Effectiveness in Peritoneal Dialysis.Biomedicines · 2024Article
- Metabolic disorders and hepatitis: Insights from a Mendelian randomization study.World journal of gastrointestinal surgery · 2024Article
- The association between hepatitis C virus infection status and blood pressure in adults in the United States: NHANES 1999-2012.Frontiers in cellular and infection microbiology · 2024Article
- Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.Antimicrobial agents and chemotherapy · 2022Article
- Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohort.Internal and emergency medicine · 2022Article
- Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study.Gut and liver · 2021Article
- Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.Clinical and molecular hepatology · 2021Article
- HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study.BMC infectious diseases · 2019Article
- Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.Journal of gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDirect-acting anti-viral agents have improved the treatment of chronic hepatitis C virus (HCV) infection, but this treatment is challenging for patients using co-medications because of potential drug-drug interactions. This study aimed to examine the comorbidities and co-medications of Japanese chronic HCV patients by age group, compared with a non-HCV patient population.
methodsThis was a retrospective observational study using a hospital-based medical claims database. We extracted data of patients with chronic HCV aged ≥18 years, and age-, sex-, and hospital-matched patients without HCV, for the period from January 2015 to November 2016, and then examined chronic comorbidities, long-term co-medications, and medications prescribed at least once during the study period.
resultsWe analysed data from 128,967 chronic HCV patients and 515,868 non-HCV patients. The median age was 70 years, and 51.0% of patients were male. More chronic HCV patients than non-HCV patients (70.5% vs. 47.1%) had at least one comorbidity, and older patients had more comorbidities than younger patients. The most common comorbidities in chronic HCV patients were diseases of oesophagus, stomach and duodenum (41.7%), followed by hypertensive diseases (31.4%). Chronic HCV patients used co-medications more commonly than non-HCV patients, and older patients used more co-medications. The most common long-term co-medications in chronic HCV patients were proton pump inhibitors (14.0%), which were prescribed to 31.9% of chronic HCV patients at least once during the study period.
conclusionsPatients with chronic HCV in Japan had more comorbidities than patients without chronic HCV regardless of age. Particularly older patients, who constitute the majority of the HCV patient population in Japan, commonly had multiple comorbidities and used co-medications. To optimise HCV treatment, physicians need to know the exact medication profiles of patients and take appropriate action to manage drug-drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.